-
Product Insights
Amyloidosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Amyloidosis - Global Clinical Trials Review, 2025" provides an overview of Amyloidosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Amyloidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Rhabdomyosarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Rhabdomyosarcoma - Global Clinical Trials Review, 2025" provides an overview of Rhabdomyosarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Rhabdomyosarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Hyperglycemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Hyperglycemia - Global Clinical Trials Review, 2025" provides an overview of Hyperglycemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Sleep Apnea Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Sleep Apnea - Global Clinical Trials Review, 2025" provides an overview of Sleep Apnea Clinical trials scenario. This report provides top line data relating to the clinical trials on Sleep Apnea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Vulvovaginal Candidiasis (VVC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in VVC Therapeutics. In 2024 and 2029, China is anticipated to have the highest number of lifetime diagnosed prevalent cases of VVC, representing a large portion of global cases. In 2024. Currently, the VVC market is saturated with generic drugs, and the lanosterol 14 alpha demethylase inhibitor drug class dominates the approved innovator drugs to treat VVC. The VVC pipeline holds nine molecules, with one asset in...
-
Sector Analysis
Clostridioides difficile Infections (CDI) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in CDI Therapeutics. In 2024, there were more than 2.04 million diagnosed incident cases of CDI in the 16 countries covered in GlobalData’s epidemiology forecast. The current CDI market is dominated by several companies marketing genericized antibiotic therapies. The CDI pipeline holds 48 molecules, with five molecule present in Phase III development. Over the past 10 years, commercial sponsors headed trials for CDI, led by Pfizer (seven...
-
Sector Analysis
Chronic Hepatitis B (CHB) Epidemiology Analysis and Forecast to 2034
Chronic hepatitis B (CHB) is a liver disease caused by the hepatitis B virus (HBV). HBV is transmitted via blood, semen, and other body fluids, and is commonly spread through sexual contact, needle sharing, accidental needlesticks, and vertically from a pregnant person to the newborn (Mayo Clinic, 2024). HBV infection can be prevented with a vaccine. For most people, HBV infection is a short-term, acute illness resulting in a full recovery in less than six months. For others, infection lasts...
-
Sector Analysis
Paraguay and Panama Update Drug Pricing Methodology and Advance Towards International Reference Pricing
Paraguay and Panama are the latest countries in Latin America to have modernized and updated their drug pricing methodologies by finally adopting generalized International Reference Pricing (IRP) schemes.
-
Sector Analysis
Eosinophilic Esophagitis (EoE) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2030
This report covers the US and provides an Excel-based forecast model for the EoE market through 2030. The current standard of care for EoE includes proton pump inhibitors, swallowed topical corticosteroids, and dietary elimination approaches. While biologics such as dupilumab have introduced new options, many patients experience partial response, relapse upon treatment discontinuation, or challenges with long-term adherence to dietary regimens. The US EoE market is expected to grow to $1.2B, driven by the introduction of biologics and the late-stage...
-
Sector Analysis
Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
The Alzheimer’s Disease therapeutics market is entering a period of significant expansion, supported by advances in disease-modifying treatments and the growing approval of anti-Aβ monoclonal antibodies. As treatment innovation accelerates and diagnosis improves, the market is poised for substantial long-term growth across major global healthcare systems. GlobalData estimates that the Alzheimer’s Disease (AD) market across the eight major markets (8MM)—the US, France, Germany, Italy, Spain, the UK, Japan, and China—was valued at $2.4 billion in 2023. The market encompasses sales...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.